Companies
DiagnosTear
its TearX platform recently reported interim clinical study results showing excellent correlation between its Red Eye test and quantitative ELISA testing, alongside French regulatory approval and a new clinical study initiated with Alyatec.
- Country
- France
Growth
TearX Red Eye test
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Private equity round of CAD 925,000 closed in November 2025 | marketscreener.com · newsfilecorp.com |
| Funding | Private equity round of USD 1.0 million in October 2025 | marketscreener.com · newsfilecorp.com |
| Funding | Private equity round of CAD 700,000 announced in June 2025 | marketscreener.com · newsfilecorp.com |
| Capacity | Plastic injection mold completed for production of 100,000 TeaRx Red Eye devices; company has access to potential capacity for millions of units through shareholder Elcam | diagnostear.com · news.futunn.com · stockhouse.com |
| Certification | TeaRx Dry Eye holds CE-IVD approval | diagnostear.com |
| Regulatory approval | Obtained regulatory and ethics approvals in France for TeaRx Red Eye clinical study as of February 2026 | marketscreener.com |
| Revenue | Company is pre-revenue and maintains annual revenues of less than $10 million | stockhouse.com · barchart.com |
Independent sources: barchart.com · marketscreener.com · news.futunn.com · newsfilecorp.com · stockhouse.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Tear-fluid biopsy | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.